Science Corp. Secures $230 Million to Bring Revolutionary Retinal Implant to Americans
The company's wireless retinal implant, PRIMA, is set to transform the lives of those with late-stage macular degeneration.
In a significant development for healthcare innovation, Science Corporation has raised an impressive $230 million to bring its groundbreaking retinal implant, PRIMA, to the American market. This funding round, led by prominent investors such as Lightspeed Venture Partners and Khosla Ventures, marks a pivotal moment in the company's journey to revolutionize vision restoration for those affected by late-stage macular degeneration.
A Visionary Approach to Vision Restoration
PRIMA is a cutting-edge system that combines glasses projecting near-infrared light with a retinal implant. Clinical trial results, published in the New England Journal of Medicine, demonstrate its remarkable effectiveness. After 12 months, participants experienced restored central vision and improved visual acuity, offering a glimmer of hope to those living with this debilitating condition.
A Step Towards Widespread Accessibility
The $230 million investment is a testament to the investors' confidence in Science Corporation's mission. With this funding, the company aims to navigate the regulatory landscape, including the crucial FDA decision on PRIMA. The expectation is that the device will be launched in Europe later this year, followed by a strategic approach to bringing it to the American market.
Impact on Healthcare and Disability
This development highlights the potential of technological advancements in healthcare, particularly for individuals with disabilities. O. Rose Broderick, a renowned health policy reporter, emphasizes the significance of such innovations in improving the lives of those with visual impairments. Her work at WNYC's Radiolab and Scientific American showcases her commitment to uncovering the stories behind groundbreaking medical technologies.
As Science Corporation prepares to make PRIMA accessible to Americans, the healthcare industry eagerly anticipates the positive impact it will have on the lives of those with late-stage macular degeneration. This funding milestone is a powerful reminder of the potential for technology to transform healthcare and offer new possibilities for those in need.
